Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | CPT1A | P50416 | 8/20 | 0.49 |
| ▸ | CPT1B | Q92523 | 8/20 | 0.49 |
| ▸ | CPT2 | P23786 | 5/20 | 0.49 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.46 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.46 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3089841 | 0.94 | KMT2A (0.55) | KMT2AMEN1CPT1ACPT1BCPT2 | |
| SCHEMBL3088413 | 0.90 | MEN1 (0.49) | KMT2AMEN1CPT1ACPT1BCPT2 | |
| SCHEMBL3088262 | 0.86 | L3MBTL1 (0.51) | KMT2AMEN1CPT1ACPT1BCPT2 | |
| SCHEMBL15062765 | 0.85 | MEN1 (0.49) | KMT2AMEN1CPT1ACPT1BAKR1C3 | |
| SCHEMBL3084581 | 0.84 | CPT1A (0.51) | KMT2AMEN1CPT1ACPT1BCPT2 | |
| SCHEMBL3082454 | 0.82 | MEN1 (0.50) | KMT2AMEN1CPT1ACPT1BL3MBTL1 | |
| SCHEMBL15062792 | 0.81 | L3MBTL1 (0.51) | KMT2AMEN1CPT1ACPT1BCPT2 | |
| SCHEMBL3100375 | 0.81 | AKR1C3 (0.64) | AKR1C3AKR1C1 | |
| SCHEMBL13261231 | 0.81 | MEN1 (0.51) | KMT2AMEN1CPT1ACPT1BL3MBTL1 | |
| SCHEMBL3088253 | 0.80 | CPT1A (0.55) | KMT2AMEN1CPT1ACPT1BCPT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2393812-B1 | SUBSTITUTED SPIROAMIDES AS B1R-MODULATORS | GRUENENTHAL GMBH (DE) | 2013-07-03 | — | — | EP | disclosed |
| US-8357717-B2 | Spiro group-containing amide compounds having bradykinin 1 receptor (B1R) activity | GRUENENTHAL GMBH (DE) | 2013-01-22 | — | — | US | disclosed |
| US-8357717-B2 | Spiro group-containing amide compounds having bradykinin 1 receptor (B1R) activity | GRUENENTHAL GMBH (DE) | 2013-01-22 | — | — | US | disclosed |
| US-8357717-B2 | Spiro group-containing amide compounds having bradykinin 1 receptor (B1R) activity | GRUENENTHAL GMBH (DE) | 2013-01-22 | — | — | US | disclosed |
| US-20100234340-A1 | Substituted Spiroamide Compounds | GRUENENTHAL GMBH (DE) | 2010-09-16 | — | — | US | disclosed |
| US-20100234340-A1 | Substituted Spiroamide Compounds | GRUENENTHAL GMBH (DE) | 2010-09-16 | — | — | US | disclosed |
| US-20100234340-A1 | Substituted Spiroamide Compounds | GRUENENTHAL GMBH (DE) | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234340-A1 | Substituted Spiroamide Compounds | BDKRB1, BDKRB2, AVPR1B | KMT2A 2897/4885MEN1 1130/4885CPT1A 4096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.